Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-02-29
2011-11-29
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
08067390
ABSTRACT:
The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein.
REFERENCES:
patent: 5030453 (1991-07-01), Lenk et al.
patent: 5962016 (1999-10-01), Willis
patent: 6506559 (2003-01-01), Driver et al.
patent: 6573099 (2003-06-01), Graham
patent: 6673611 (2004-01-01), Thompson et al.
patent: 6680068 (2004-01-01), Jain et al.
patent: 6953838 (2005-10-01), Vale, Jr. et al.
patent: 2002/0168707 (2002-11-01), Graham
patent: 2003/0012812 (2003-01-01), Tormo et al.
patent: 2003/0051263 (2003-03-01), Fire et al.
patent: 2003/0055020 (2003-03-01), Fire et al.
patent: 2003/0159161 (2003-08-01), Graham et al.
patent: 2004/0019001 (2004-01-01), McSwiggen
patent: 2004/0064842 (2004-04-01), Graham et al.
patent: 2004/0204377 (2004-10-01), Rana
patent: 2004/0208921 (2004-10-01), Ho et al.
patent: 2004/0265839 (2004-12-01), Mello et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0267027 (2005-12-01), Lounsbury et al.
patent: 2006/0134221 (2006-06-01), Geall
patent: 2006/0240093 (2006-10-01), MacLachlan et al.
patent: 2007/0135370 (2007-06-01), MacLachlan et al.
patent: 2008/0317811 (2008-12-01), Andre et al.
patent: 2009/0012021 (2009-01-01), Sood et al.
patent: WO 02/100435 (2002-12-01), None
patent: WO 03/015757 (2003-02-01), None
patent: WO 03/027327 (2003-04-01), None
patent: WO 2004/002453 (2004-01-01), None
patent: WO 2006/113679 (2006-10-01), None
patent: WO 2007/001943 (2007-01-01), None
Bailey and Sullivan, “Efficient encapsulation of DNA plasmids in small neutral liposomes induced by ethanol and calcium,”Biochimica. Biophys. Acts., 1468:239-252, 2000.
Bangham et al., “The action of steroids and streptolysin S on the permeability of phospholipid structures to cations,”J. Mol. Biol., 13:253-259, 1965.
Deamer and Uster, In: Liposome Preparation: Methods and Mechanisms, Ostro (Ed.), Liposomes, 1983.
Dokka et al., “Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes,”Pharm. Res., 17:521-25, 2000.
Donze and Picard, “RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase,”Nucleic Acids Res., 30:e46, 2002.
Duxbury et al., “EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma,”Oncogene, 23:1448-1456, 2004.
Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,”Nature, 411:494-498, 2001.
Elmén et al., “Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality,”Nucleic Acids Res., 33:439-47, 2005.
Farhood et al., “The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer,”Biochim. Biophys. Act., 1235:289-95, 1995.
Fire et al., “Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans,” Nature, 391:806-811, 1998.
Ghosh and Bachawat, In:Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands, Wu et al. (Eds.) Marcel Dekker, NY, 87-104, 1991.
Gutierrez-Puente et al., “Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2,”J. Pharmacol. Exp. Ther., 291:865-869, 1999.*
Halder et al., “Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells,”Clin. Cancer Res., 11(24 Pt. 1):8829-36, 2005.
Halder et al., “Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy,”Clin. Cancer Res., 12:4916-4924, 2006.
Huang et al., “Fluorescence characteristics of site-specific and stereochemically distinct benzo[a]pyrene diol epoxide-DNA adducts as probes of adduct conformation,”Chem. Res. Toxicol., 15:118-126, 2002.
Judge et al., “Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA,”Nat. Biotechnol., 23:457-62, 2005.
Kamat et al., “The role of relaxin in endometrial cancer,”Cancer Biol. Ther., 5:71-7, 2006.
Kaneda et al., “Increased expression of DNA cointroduced with nuclear protein in adult rat liver,”J. Mol. Med., 73:289-297, 1995.
Karashima et al., “Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8,”Clin. Cancer Res., 9:2786-2797, 2003.
Kassim et al., “Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients,”Clin. Biochem., 37:363-369, 2004.
Kato et al., “Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNa and nuclear protein by a simplified liposome method,”J. Biol. Chem., 266:3361-3364, 1991.
Kim et al., “Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice,”Neoplasia, 3:33-42, 2001.
Koch et al., “Interleukin-8 as a macrophage-derived mediator of angiogenesis,”Science, 258:1798-1801, 1992.
Kostarelos et al., “Binding and interstitial penetration of liposomes within avascular tumor spheroids,”Int. J. Cancer, 112:713-21, 2004.
Krasnici et al., “Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels,”Int. J. Cancer, 105:561-7, 2003.
Landen et al., “EphA2 as a target for ovarian cancer therapy,”Expert. Opin. Ther. Targets, 9:1179-87, 2005.
Landen et al., “Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer,”Cancer Biol. Ther., 5:1708-1713, 2006.
Landen et al., “Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery,”Cancer Res., 65:6910-18, 2005.
Lee et al., “Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer,”Cancer Res., 56:1303-1308, 1996.
Leung and Whittaker, “RNA interference: from gene silencing to gene-specific therapeutics,”Pharmacol. Ther., 107:222-239, 2005.
Li et al., “Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis,”Angiogenesis, 8:63-71, 2005.
Lokshin et al., “Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer,”Gynecol. Oncol., 102:244-251, 2006.
Lu et al., “Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma,”Cancer Res., 67:1757-68, 2007.
Luca et al., “Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis,”Am. J. Pathol., 151:1105-1113, 1997.
Matsushima and Oppenheim, “Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF,”Cytokine, 1:2-13, 1989.
Mian et al., “Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB,”Clin. Cancer Res., 9:3167-3175, 2003.
Miller et al., “Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes,”Biochemistry, 37:12875-83, 1998.
Murdoch et al., “Cxc chemokine receptor expression on human endothelial cells,”Cytokine, 11:704-12, 1999.
Nicolau et al., “Liposomes as carriers for in vivo gene transfer an
Bar-Eli Menashe
Lopez-Berestein Gabriel
Merritt William M.
Sood Anil K.
Fulbright & Jaworski L.L.P.
The Board of Regents of the University of Texas System
Whiteman Brian
LandOfFree
Therapeutic targeting of interleukins using siRNA in neutral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic targeting of interleukins using siRNA in neutral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic targeting of interleukins using siRNA in neutral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296338